Literature DB >> 9303420

In vitro susceptibilities to amphotericin B, itraconazole, and miconazole of filamentous fungi isolated from patients with cystic fibrosis.

C Hennequin1, N Benailly, C Silly, M Sorin, P Scheinmann, G Lenoir, J L Gaillard, P Berche.   

Abstract

The antimicrobial activities of amphotericin B, itraconazole, and miconazole against 101 filamentous fungi from patients with cystic fibrosis were tested by a reproducible microdilution method. Itraconazole was very active against Aspergillus species and Scedosporium species (MIC at which 90% of the isolates were inhibited [MIC90], 0.06 to 0.5 mg/liter), whereas amphotericin B was less effective (MIC90, 0.5 to 8 mg/liter).

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9303420      PMCID: PMC164071          DOI: 10.1128/AAC.41.9.2064

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  11 in total

1.  Invasive aspergillosis after bilateral lung transplantation in cystic fibrosis.

Authors:  M Drent; M T van Rens; S S Wagenaar; B M de Jongh; H van Velzen-Blad; J M van den Bosch
Journal:  Respir Med       Date:  1995-07       Impact factor: 3.415

Review 2.  Antifungal susceptibility testing: technical advances and potential clinical applications.

Authors:  M A Pfaller; J H Rex; M G Rinaldi
Journal:  Clin Infect Dis       Date:  1997-05       Impact factor: 9.079

3.  Itraconazole and allergic bronchopulmonary aspergillosis in twin brothers with cystic fibrosis.

Authors:  G P Mannes; S van der Heide; W M van Aalderen; J Gerritsen
Journal:  Lancet       Date:  1993-02-20       Impact factor: 79.321

4.  Treatment of invasive aspergillosis with itraconazole.

Authors:  D W Denning; R M Tucker; L H Hanson; D A Stevens
Journal:  Am J Med       Date:  1989-06       Impact factor: 4.965

5.  Allergic bronchopulmonary aspergillosis in patients with cystic fibrosis.

Authors:  S Mroueh; A Spock
Journal:  Chest       Date:  1994-01       Impact factor: 9.410

6.  Disseminated aspergillosis in a patient with cystic fibrosis and allergic bronchopulmonary aspergillosis.

Authors:  Y Chung; J R Kraut; A M Stone; J Valaitis
Journal:  Pediatr Pulmonol       Date:  1994-02

Review 7.  Microbiology of airway disease in patients with cystic fibrosis.

Authors:  P H Gilligan
Journal:  Clin Microbiol Rev       Date:  1991-01       Impact factor: 26.132

8.  Adjunctive therapy of allergic bronchopulmonary aspergillosis with itraconazole.

Authors:  D W Denning; J E Van Wye; N J Lewiston; D A Stevens
Journal:  Chest       Date:  1991-09       Impact factor: 9.410

Review 9.  Allergic bronchopulmonary mycosis complicating cystic fibrosis.

Authors:  A Knutsen; R G Slavin
Journal:  Semin Respir Infect       Date:  1992-09

10.  Comparative and collaborative evaluation of standardization of antifungal susceptibility testing for filamentous fungi.

Authors:  A Espinel-Ingroff; K Dawson; M Pfaller; E Anaissie; B Breslin; D Dixon; A Fothergill; V Paetznick; J Peter; M Rinaldi
Journal:  Antimicrob Agents Chemother       Date:  1995-02       Impact factor: 5.191

View more
  3 in total

1.  Sputum itraconazole concentrations in cystic fibrosis patients.

Authors:  I Sermet-Gaudelus; A Lesne-Hulin; G Lenoir; E Singlas; P Berche; C Hennequin
Journal:  Antimicrob Agents Chemother       Date:  2001-06       Impact factor: 5.191

2.  Genotyping study of Scedosporium apiospermum isolates from patients with cystic fibrosis.

Authors:  Alain Defontaine; Rachid Zouhair; Bernard Cimon; Jacqueline Carrère; Eric Bailly; Françoise Symoens; Mohammed Diouri; Jean-Noel Hallet; Jean-Philippe Bouchara
Journal:  J Clin Microbiol       Date:  2002-06       Impact factor: 5.948

Review 3.  Ecology of Scedosporium Species: Present Knowledge and Future Research.

Authors:  A Rougeron; S Giraud; A Alastruey-Izquierdo; J Cano-Lira; J Rainer; A Mouhajir; S Le Gal; G Nevez; W Meyer; J P Bouchara
Journal:  Mycopathologia       Date:  2017-09-19       Impact factor: 2.574

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.